Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies

Trial Profile

A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid Malignancies

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tigilanol tiglate (Primary)
  • Indications Carcinoma; Head and neck cancer; Laryngeal cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors QBiotics

Most Recent Events

  • 07 May 2025 Planned number of patients changed from 37 to 20.
  • 16 Aug 2023 According to a QBiotics Group Limited media release, QBiotics decided to end phase I/II trial (QB46C-H03) on the basis it had sufficient safety information to inform the Company's subsequent Human Clinical Phase II efficacy trial in head and neck cancer which is now open at multiple sites in Australia and the UK.
  • 08 Jun 2023 According to a QBiotics Group Limited media release, data from this study will be presented at BIO International Convention through 5-8 June in Boston.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top